Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5*3/*3 nonexpressors

Transplant Immunology

Volumn 15, Issue 3, 2006, Pages 235-240

  Wang, Jian ^a   Zeevi, Adriana ^b   McCurry, Kenneth ^b   Schuetz, Erin ^c   Zheng, HongXia ^a   Iacono, Aldo ^b   McDade, Kevin ^b   Zaldonis, Diana ^b   Webber, Steven ^b   Watanabe, Richard M ^a   Burckart, Gilbert J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ABCB1 haplotype; CYP3A5; Lung transplantation; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; DNA; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; TACROLIMUS;

ABCB1 GENE; ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; DOSE RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LETHAL DOSE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS; TIME FACTORS;

EID: 31144450792     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2005.08.001     Document Type: Article

References (30)

1. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano Human P-glycoprotein transports cyclosporin A and FK506 J Biol Chem 268 9 1993 6077 6080
2. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci U S A 84 21 1987 7735 7738
3. V.S. Donnenberg, G.J. Burckart, B.P. Griffith, A.B. Jain, A. Zeevi, and A.D. Berg P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients J Clin Pharmacol 41 12 2001 1271 1279
4. C. Marzolini, E. Paus, T. Buclin, and R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 1 2004 13 33
5. M. Schwab, M. Eichelbaum, and M.F. Fromm Genetic polymorphisms of the human MDR1 drug transporter Annu Rev Pharmacol Toxicol 43 2003 285 307
6. E.L. Woodahl, and R.J. Ho The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function Curr Drug Metab 5 1 2004 11 19
7. D. Anglicheau, C. Verstuyft, P. Laurent-Puig, L. Becquemont, M.H. Schlageter, and B. Cassinat Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients J Am Soc Nephrol 14 7 2003 1889 1896
8. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, and P. Bowman Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms Am J Transplant 3 4 2003 477 483
9. V. Haufroid, M. Mourad, V. Van Kerckhove, J. Wawrzyniak, M. De Meyer, and D.C. Eddour The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 3 2004 147 154
10. N. Tsuchiya, S. Satoh, H. Tada, Z. Li, C. Ohyama, and K. Sato Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 8 2004 1182 1187
11. M. Goto, S. Masuda, T. Kiuchi, Y. Ogura, F. Oike, and M. Okuda CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation Pharmacogenetics 14 7 2004 471 478
12. M. Goto, S. Masuda, H. Saito, S. Uemoto, T. Kiuchi, and K. Tanaka C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation Pharmacogenetics 12 6 2002 451 457
13. H. Tada, N. Tsuchiya, S. Satoh, H. Kagaya, Z. Li, and K. Sato Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 4 2005 1730 1732
14. D.A. Hesselink, R.H. van Schaik, I.P. van der Heiden, M. van der Werf, P.J. Gregoor, and J. Lindemans Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 3 2003 245 254
15. H. Zheng, A. Zeevi, E. Schuetz, J. Lamba, K. McCurry, and B.P. Griffith Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism J Clin Pharmacol 44 2 2004 135 140
16. I.A. Macphee, S. Fredericks, T. Tai, P. Syrris, N.D. Carter, and A. Johnston Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 11 2002 1486 1489
17. I. Mai, E.S. Perloff, S. Bauer, M. Goldammer, A. Johne, and G. Filler MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients Br J Clin Pharmacol 58 5 2004 548 553
18. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, and C. Meisel Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin Pharmacol Ther 72 5 2002 584 594
19. D.L. Kroetz, C. Pauli-Magnus, L.M. Hodges, C.C. Huang, M. Kawamoto, and S.J. Johns Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene Pharmacogenetics 13 8 2003 481 494
20. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, and U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2 2001 189 199
21. D. Anglicheau, C. Legendre, and E. Thervet Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives Transplantation 78 3 2004 311 315
22. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, and J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 4 2001 383 391
23. E. Thervet, D. Anglicheau, B. King, M.H. Schlageter, B. Cassinat, and P. Beaune Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients Transplantation 76 8 2003 1233 1235
24. I.A. MacPhee, S. Fredericks, T. Tai, P. Syrris, N.D. Carter, and A. Johnston The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 6 2004 914 919
25. I.A. Macphee, S. Fredericks, M. Mohamed, M. Moreton, N.D. Carter, and A. Johnston Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians Transplantation 79 4 2005 499 502
26. K. Tang, S.M. Ngoi, P.C. Gwee, J.M. Chua, E.J. Lee, and S.S. Chong Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations Pharmacogenetics 12 6 2002 437 450
27. S. Ozawa, A. Soyama, M. Saeki, H. Fukushima-Uesaka, M. Itoda, and S. Koyano Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1 Drug Metab Pharmacokinet 19 2 2004 83 95
28. P.A. Andrews, M. Sen, and R.W. Chang Racial variation in dosage requirements of tacrolimus Lancet 348 9039 1996 1446
29. J.F. Neylan Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine, FK506 Kidney Transplant Study Group Transplantation 65 4 1998 515 523
30. L.M. Mancinelli, L. Frassetto, L.C. Floren, D. Dressler, S. Carrier, and I. Bekersky The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups Clin Pharmacol Ther 69 1 2001 24 31